Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

129.25GBp
4:14am EDT
Price Change (% chg)

-2.75p (-2.08%)
Prev Close
132.00p
Open
131.50p
Day's High
131.75p
Day's Low
127.75p
Volume
78,590
Avg. Vol
411,566
52-wk High
171.50p
52-wk Low
100.47p

VEC.L

Chart for VEC.L

About

Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura’s products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company’s pharmaceutical business... (more)

Overall

Beta: -0.21
Market Cap (Mil.): £531.20
Shares Outstanding (Mil.): 402.42
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 33.37 34.07
EPS (TTM): -0.01 -- --
ROI: -1.08 18.15 17.40
ROE: -1.27 18.85 18.25
Search Stocks

BRIEF-Vectura says partner Novartis signs marketing deal with Pfizer UK

* Announcement of commercial arrangement with Pfizer UK to promote Ultibro Breezhaler and Seebri Breezhaler in United Kingdom Source text for Eikon: Further company coverage:

04 Sep 2014

BRIEF-Vectura performance from April to date in line with board's expectations

* Product pipeline is progressing in line with board's expectations

19 Aug 2014

BRIEF-Vectura says in US collaboration agreement for VR506 asthma therapy

* Announces a further US collaboration agreement with a leading international pharmaceutical company for VR506 asthma therapy

30 Jun 2014

UPDATE 2-Vectura revenue jumps on royalty push, sees more growth

* Shares rise as much as 3.5 pct (Adds CEO and analyst comments; updates share movement)

21 May 2014

Vectura revenue rises 20 pct on higher royalty payments

May 21 - Drug developer Vectura Group Plc reported a 20 percent rise in full-year revenue as it benefited from higher royalty payments for drugs it has licensed.

21 May 2014

BRIEF-Vectura Group revenue rises 20 pct

* FY revenue rises 20 percent to 36.5 million stg (2012/13: 30.5 million stg)

21 May 2014

BRIEF-Vectura to initiate study for asthama medicine Favolir in Europe

* Will initiate a pivotal study in Europe later this calendar year for Favolir, its investigational product for severe, uncontrolled asthma

11 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00
Provider: Peel Hunt
$23.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks